TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

NANJING

OncologyInfectious DiseaseImmunology
Generics

NANJING is a generic drug manufacturer focused on Oncology, Infectious Disease, Immunology.

2020
Since
1
Drugs
-
Trials
27
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

CELECOXIB 2026-02-12
Labeling
CELECOXIB 2025-10-21
Labeling
CELECOXIB 2025-10-15
Labeling
CELECOXIB 2025-10-15
Labeling
CELECOXIB 2025-09-26
Labeling
CELECOXIB 2025-09-26
Labeling
CELECOXIB 2025-09-26
Labeling
CELECOXIB 2025-08-04
Labeling
CELECOXIB 2025-07-14
CELECOXIB 2025-04-29
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 69%
0 drugs Phase 3: 10 Phase 2: 11 Phase 1: 47
Infectious Disease 15%
0 drugs Phase 3: 4 Phase 2: 3 Phase 1: 2
Immunology 8%
0 drugs Phase 2: 2 Phase 1: 8
Respiratory 4%
0 drugs Phase 2: 3 Phase 1: 1
Gastroenterology 4%
0 drugs Phase 3: 1 Phase 1: 3

Pipeline Strength Pro

Loading...

Competitors Pro

Pfizer big-pharma
Oncology, Infectious Disease, Immunology, Gastroenterology
GSK big-pharma
Infectious Disease, Respiratory, Oncology, Immunology
Sanofi big-pharma
Oncology, Infectious Disease, Immunology, Respiratory
Gilead Sciences biotech
Infectious Disease, Oncology, Immunology, Gastroenterology, Respiratory
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology, Infectious Disease